Eli Lilly bags an early-stage biotech for the neuro team — paying $135M cash and offering $1B-plus in milestones
Eli Lilly is snapping up a little Cambridge-based biotech to add to their neuro group.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
